Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1119454 | 1.00 | POLB (0.44) | POLBGAAG6PC1HSP90AA1MAPK1 | |
| SCHEMBL1119493 | 1.00 | POLB (0.44) | POLBGAAG6PC1HSP90AA1MAPK1 | |
| SCHEMBL316481 | 0.98 | POLB (0.45) | POLBGAAG6PC1HSP90AA1MAPK1 | |
| SCHEMBL1119433 | 0.93 | ALDH1A1 (0.42) | POLBGAASMN1; SMN2KDM4EMAOB | |
| SCHEMBL674275 | 0.87 | MAOB (0.46) | POLBGAASMN1; SMN2MAOBMAPT | |
| SCHEMBL164340 | 0.77 | MAOA (0.51) | MAOB | |
| SCHEMBL933856 | 0.77 | MAOA (0.51) | MAOB | |
| SCHEMBL8910489 | 0.77 | CYP2C19 (0.40) | POLBHSP90AA1MAPK1SMN1; SMN2KDM4E | |
| SCHEMBL6002937 | 0.77 | SLC18A3 (0.48) | MAOB | |
| SCHEMBL7055107 | 0.77 | TRPM8 (0.44) | POLBSMN1; SMN2MAOBMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 460 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4382546-A1 | POLY(UREA-URETHANE) POLYMER | BASF SE (DE) | 2024-06-12 | — | — | EP | claimed |
| WO-2024105029-A1 | RECYCLABLE POLY(UREA-URETHANE) POLYMER AND COMPOSITE WITH DYNAMIC HINDERED UREA BONDS (HUBS) | BASF SE (DE) | 2024-05-23 | — | — | WO | claimed |
| EP-1592738-B1 | RESIN COMPOSITIONS | CIBA HOLDING INC (CH) | 2020-07-29 | — | — | EP | claimed |
| EP-3277649-B1 | TRANSALKYLATED CYCLOHEXYLBENZYL AND BIPHENYL COMPOUNDS | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2019-08-21 | — | — | EP | claimed |
| US-10017433-B2 | Transalkylated cyclohexylbenzyl and biphenyl compounds | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2018-07-10 | — | — | US | claimed |
| US-20180050971-A1 | Transalkylated Cyclohexylbenzyl and Biphenyl Compounds | EXXONMOBIL CHEMICAL PATENTS INC. | 2018-02-22 | — | — | US | claimed |
| EP-3277649-A1 | TRANSALKYLATED CYCLOHEXYLBENZYL AND BIPHENYL COMPOUNDS | ExxonMobil Chemical Patents Inc. (US) | 2018-02-07 | — | — | EP | claimed |
| CN-107438590-A | The cyclohexyl benzyl and biphenol compound of transfering alkylation | 埃克森美孚化学专利公司 | 2017-12-05 | — | — | CN | claimed |
| CN-106432571-A | Polymer composition and process for making the same | 爱伦环球有限公司 | 2017-02-22 | — | — | CN | claimed |
| US-20170030015-A1 | POLYMER COMPOSITION AND PROCESS FOR MAKING THE SAME | ARON UNIVERSAL LTD. (IN) | 2017-02-02 | — | — | US | claimed |
| US-5639775-A | COGNITION ACTIVATORS | THE UNIVERSITY OF TOLEDO (US) | 1997-06-17 | — | — | US | claimed |
| US-5633382-A | Histamine H3 -receptor antagonists and therapeutic uses thereof | THE UNIVERSITY OF TOLEDO (US) | 1997-05-27 | — | — | US | claimed |
| EP-0480659-B1 | Use of Angiotensin-II antagonists for the manufacture of a medicament for the treatment of hyperuricemia | MERCK & CO INC (US) | 1996-09-04 | — | — | EP | claimed |
| EP-0633882-A1 | 4- 4'-PIPERIDINYL OR 3'-PIRROLIDINYL] SUBSTITUTED IMIDAZOLES AS H3-RECEPTOR ANTAGONISTS AND THERAPEUTIC USES THEREOF | THE UNIVERSITY OF TOLEDO (US) | 1995-01-18 | — | — | EP | claimed |
| EP-0242618-B1 | Transparent optical article and process for preparing same | NIPPON OILS & FATS CO LTD (JP) | 1994-11-02 | — | — | EP | claimed |
| US-5260322-A | Angiotension II antagonists in the treatment of hyperuricemia | MERCK & CO., INC. (US) | 1993-11-09 | — | — | US | claimed |
| WO-1993020061-A1 | 4-[4'-PIPERIDINYL OR 3'-PIRROLIDINYL] SUBSTITUTED IMIDAZOLES AS H3-RECEPTOR ANTAGONISTS AND THERAPEUTIC USES THEREOF | THE UNIVERSITY OF TOLEDO (US) | 1993-10-14 | — | — | WO | claimed |
| EP-0480659-A2 | Use of Angiotensin-II antagonists for the manufacture of a medicament for the treatment of hyperuricemia | MERCK & CO. INC. (US) | 1992-04-15 | — | — | EP | claimed |
| EP-0242618-A2 | Transparent optical article and process for preparing same | NIPPON OIL AND FATS COMPANY, LIMITED (JP) | 1987-10-28 | — | — | EP | claimed |
| US-3971804-A | ACARICIDES, FUNGICIDES, INSECTICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017433-B2 | Transalkylated cyclohexylbenzyl and biphenyl compounds | DDT, CYP2B6, AHR | POLB 430/4885GAA 1725/4885G6PC1 4721/4885 |
| US-20180050971-A1 | Transalkylated Cyclohexylbenzyl and Biphenyl Compounds | DDT, CYP2B6, AHR | POLB 430/4885GAA 1725/4885G6PC1 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.